Combined use of waist and hip circumference to identify abdominally obese HIV-infected patients at increased health risk

Trevor O'Neill, Giovanni Guaraldi, Gabriella Orlando, Federica Carli, Elisa Garlassi, Stefano Zona, Jean-Pierre Després, Robert Ross, Trevor O'Neill, Giovanni Guaraldi, Gabriella Orlando, Federica Carli, Elisa Garlassi, Stefano Zona, Jean-Pierre Després, Robert Ross

Abstract

Objectives: To determine whether for a given waist circumference (WC), a larger hip circumference (HC) was associated with a reduced risk of insulin resistance, type 2 diabetes (T2D), hypertension and cardiovascular disease (CVD) in HIV-infected patients. A second objective was to determine whether, for a given WC, the addition of HC improved upon estimates of abdominal adiposity, in particular visceral adipose tissue (VAT), compared to those obtained by WC alone.

Methods: HIV-infected men (N = 1481) and women (N = 841) were recruited between 2005 and 2009. WC and HC were obtained using standard techniques and abdominal adiposity was measured using computed tomography.

Results: After control for WC and covariates, HC was negatively associated with risk of insulin resistance (p<0.05) and T2D [Men: OR = 0.91 (95% CI: 0.86-0.96); Women: OR = 0.91 (95% CI: 0.84-0.98)]. For a given WC, HC was also negatively associated with a lower risk of hypertension (p<0.05) and CVD [OR = 0.94 (95% CI: 0.88-0.99)] in men, but not women. Although HC was negatively associated with VAT in men and women after control for WC (p<0.05), the addition of HC did not substantially improve upon the prediction of VAT compared to WC alone.

Conclusions: The identification of HIV-infected individuals at increased health risk by WC alone is substantially improved by the addition of HC. Estimates of visceral adipose tissue by WC are not substantially improved by the addition of HC and thus variation in visceral adiposity may not be the conduit by which HC identifies increased health risk.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Seidell JC, Han TS, Feskens EJ, Lean ME (1997) Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. J Intern Med 242: 401–406.
    1. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, et al. (2003) Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am J Clin Nutr 77: 1192–1197.
    1. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, et al. (2004) Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. Diabetes Care 27: 372–377.
    1. Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, et al. (2004) Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord 28: 402–409.
    1. Snijder MB, Dekker JM, Visser M, Yudkin JS, Stehouwer CD, et al. (2003) Larger thigh and hip circumferences are associated with better glucose tolerance: the Hoorn study. Obes Res 11: 104–111.
    1. Parker ED, Pereira MA, Stevens J, Folsom AR (2009) Association of hip circumference with incident diabetes and coronary heart disease: the Atherosclerosis Risk in Communities study. Am J Epidemiol 169: 837–847.
    1. de Koning L, Gerstein HC, Bosch J, Diaz R, Mohan V, et al. (2010) Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. Diabetologia 53: 1322–1330.
    1. Seidell JC, Perusse L, Despres JP, Bouchard C (2001) Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr 74: 315–321.
    1. Lissner L, Bjorkelund C, Heitmann BL, Seidell JC, Bengtsson C (2001) Larger hip circumference independently predicts health and longevity in a Swedish female cohort. Obes Res 9: 644–646.
    1. Heitmann BL, Frederiksen P, Lissner L (2004) Hip circumference and cardiovascular morbidity and mortality in men and women. Obes Res 12: 482–487.
    1. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, et al. (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366: 1640–1649.
    1. Heitmann BL, Frederiksen P (2009) Thigh circumference and risk of heart disease and premature death: prospective cohort study. BMJ 339: b3292.
    1. Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, et al. (2007) Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation 116: 2933–2943.
    1. Bigaard J, Frederiksen K, Tjonneland A, Thomsen BL, Overvad K, et al. (2004) Waist and hip circumferences and all-cause mortality: usefulness of the waist-to-hip ratio? Int J Obes Relat Metab Disord 28: 741–747.
    1. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB (2008) Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation 117: 1658–1667.
    1. Cameron AJ, Magliano DJ, Shaw JE, Zimmet PZ, Carstensen B, et al. (2012) The influence of hip circumference on the relationship between abdominal obesity and mortality. Int J Epidemiol 41: 484–494.
    1. Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444: 881–887.
    1. Kuk JL, Janiszewski PM, Ross R (2007) Body mass index and hip and thigh circumferences are negatively associated with visceral adipose tissue after control for waist circumference. Am J Clin Nutr 85: 1540–1544.
    1. Villarroya F, Domingo P, Giralt M (2010) Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim Biophys Acta 1801: 392–399.
    1. Expert Committee on the D, Clasification of Diabetes M (2002) American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 25 Suppl 1S1–147.
    1. Sakai Y, Ito H, Egami Y, Ohoto N, Hijii C, et al. (2005) Favourable association of leg fat with cardiovascular risk factors. J Intern Med 257: 194–200.
    1. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, et al. (2005) Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 40: 121–131.
    1. Study of Fat R, Metabolic Change in HIVI (2006) Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 42: 562–571.
    1. Tien PC, Cole SR, Williams CM, Li R, Justman JE, et al. (2003) Incidence of lipoatrophy and lipohypertrophy in the women’s interagency HIV study. J Acquir Immune Defic Syndr 34: 461–466.
    1. Andersen O, Haugaard SB, Andersen UB, Friis-Moller N, Storgaard H, et al. (2003) Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 52: 1343–1353.
    1. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC (2000) Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 25: 312–321.
    1. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, et al. (2001) Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32: 130–139.
    1. Lake JE, Wohl D, Scherzer R, Grunfeld C, Tien PC, et al. (2011) Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care 23: 929–938.
    1. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J (2010) HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 16: 218–229.
    1. Orlando G, Guaraldi G, Zona S, Carli F, Bagni P, et al. (2012) Ectopic fat is linked to prior cardiovascular events in men with HIV. J Acquir Immune Defic Syndr 59: 494–497.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅